|
| |
 |
|
| EDITORIAL |
|
| Year : 2018 | Volume
: 29
| Issue : 3 | Page : 119 |
|
Management of metastasis renal cell carcinoma: Where are we heading?
See-Tong Pang
Department of Surgery, Division of Urology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| Date of Web Publication | 27-Jun-2018 |
Correspondence Address:
See-Tong Pang
Department of Surgery, Division of Urology, Linkou Chang Gung Memorial Hospital, No 5 Fushing Street, Kwei Shan, Taoyuan
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/UROS.UROS_90_18
How to cite this article:
Pang ST. Management of metastasis renal cell carcinoma: Where are we heading?. Urol Sci 2018;29:119 |
Metastasis renal cell carcinoma (mRCC) is still a cancer that remains great challenges to physician and patients. mRCC is well known for its resistant ability to radiation therapy and chemotherapy. Despite all the affords, we have come to a period of time that we can prolong the progression-free survival of mRCC patient using targeted therapy. Many targeted therapy drugs are now available for treating mRCC. The patient can be treated with these drugs up to 3–4 line, but so far, there is no consensus in the sequencing of the drug treatment. However, despite all these treatments, many patients may still die of the cancer progression. After more than a decade of targeted therapy development, we are now entering a new phase of immunotherapy that is different from the traditional immunotherapy with the usage of high-dose interleukin therapy. This novel immunotherapy is targeting the immune check-point process that can overcome the immune suppression caused by the tumor.
To find the best drug and sequencing of the drug usage are the current major issues. Currently, the best regimen for each patient remains a challenging work. Apply of biomarkers to select the optimal drug for our patient is needed.
|
Search Pubmed for